| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2023: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2022: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Outline of Annual Research Achievements |
I advanced the identification of enhancing antibodies in SARS-CoV-2 variants. First, I discovered that Wild-type enhancing antibodies can also enhance the infection of the Delta variant. I also analyzed the mechanism of the enhancing antibodies. This part of the work has been made public on Biorxiv. Subsequently, the project has been extended from the initial Delta variant to the recently emerged Omicron XBB1.5 variant, which analyzes the functional mechanism of the enhancing antibody, and will be supplemented with data from JN.1 based on peer-review. Currently, the experiment on this topic is almost completed, and we plan to submit a manuscript in the near future.
Last year, I unexpectedly found that some RBD antibodies could enhance Delta pseudovirus infection in 293T-ACE2 at low concentrations. Further studies revealed a specific enhancement only on human ACE2, but not on monkey ACE2 cells. Also, I found that the enhancing effect of RBD antibody on high expression ACE2 but not low expression ACE2, similar to other research. Through the study, the relationship between high expression of ACE2 and antibody-enhanced viral infection was found. My next plan is to analyze and clarify the enhancement mechanism of RBD antibody, and complete the manuscript writing and publication.
During the two-year funding period, I presented once at the JSI annual meeting, published a review article as the first author introducing enhancing antibodies and SARS-CoV-2 antibodies, and also published a preprint article. As a main contributor, I co-authored three articles that were formally published.
|
